A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treatment Adherence of Subjects With Dyslipidemia in Thailand

NCT05370703 | Completed

• 1 other identifier: EPID-I21-0159
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

A prospective, randomized, open-label, clinical study to evaluate the effect of mobile applications "My A:Care" and "Smart Coach" on the lipid-lowering treatment adherence of subjects with dyslipidemia in Thailand

Conditions

Dyslipidemia

Outcome Measures

Primary Outcomes (1)

• Impact of mobile applications (My A:Care and Smart Coach) on adherence to the lipid-lowering therapy in subjects with dyslipidemia using MARS-5VA questionnaire

  Adherence is measured by change from Baseline in MARS-5VA Scores at 12 Weeks

  12 weeks (± 7 days)

Secondary Outcomes (3)

• Impact of mobile applications (My A:Care and Smart Coach) on level of lipid control in subjects with dyslipidemia by measuring the subject's lipid profile

  12 weeks (± 7 days)

• Impact of mobile applications (My A:Care and Smart Coach) on the subjects' perception to medications in general using BMQ-General-12 and PSM-5 Questionnaires

  12 weeks (± 7 days)

• Impact of mobile applications (My A:Care and Smart Coach) on the subjects' perception to medications specific to lipid-lowering therapy using BMQ-S11-Plural and MAIN Screen Questionnaires

  12 weeks (± 7 days)

Other Outcomes (1)

• Correlations between subjects' adherence to lipid-lowering therapy and mobile applications data using individual summaries retrieved from the application database.

  12 weeks (± 7 days)

Study Arms (3)

Standard of Care (SOC) group

This group will continue their current lipid-lowering therapy and will not need to download any mobile application.

SOC + My A:Care group:

This group will continue their current lipid-lowering therapy along with access to the mobile application My A:Care that supports medication adherence through motivational messages and challenges, health insights, and medication reminders.

Behavioral: My A:care

SOC + Smart Coach group:

This group will continue their current lipid-lowering therapy along with access to the mobile application Smart Coach that supports medication adherence through personalized motivational messages and challenges, health insights, and medication reminders. Personalization of the messages and challenges will be based on a behavioral profiling Social, Psychological, Usage, Rational (SPUR™) questionnaire that is completed at randomization to the Smart Coach application. Study site will guide the subjects on how to use these mobile applications. Eligibility assessment will be based on information collected at screening/baseline visit (Visit 1) and assessment of Part 1 of MARS 5VA questionnaire. Adherence at baseline (Visit 1) and after 12 weeks of observation (Visit 2), will be evaluated by the complete MARS 5VA (Part 1 and 2) questionnaire. Each subject will be followed up for approximately 12 weeks from randomization at Visit 1.

Behavioral: Smart Coach

Interventions

My A:care BEHAVIORAL

Mobile application with Motivational messages

SOC + My A:Care group:

Smart Coach BEHAVIORAL

Mobile application with Motivational messages

SOC + Smart Coach group:

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This is a prospective, randomized, open-label, clinical study in subjects with dyslipidemia and suboptimal adherence to their current lipid-lowering therapy in Thailand.

You may qualify if:

• Male and female subjects aged 18-75 years (inclusive)
• Subjects who have provided written informed consent
• Subjects who were diagnosed with dyslipidemia and initiated lipid-lowering therapy based on local treatment guidelines, between 9 months and 1 month prior to the screening visit
• Subjects who were on a stable lipid-lowering therapy within 1 month prior to the screening visit
• Subjects who are not compliant with the prescribed lipid-lowering therapy, assessed as having \<22 points score on the Part 1 of MARS-5VA questionnaire at the screening visit
• Subjects for whom lipid profile laboratory data is available from routine care within 14 days prior to the screening visit
• Subject must have their own Android operating system smart phone and a data package suitable for the installation and running of the mobile application and sending and receiving data
• Willing and able to operate the mobile devices, including use of all study-related smartphone applications; able to proof regular use of mobile applications in their daily life.
• Able to read and understand Thai
• Willing and able to comply with the study requirements.

You may not qualify if:

• Subjects who are diagnosed with myocardial infarction or stroke or unstable angina within 2 months prior to screening, subjects who are hospitalized for their cardio-vascular condition and requiring changes in administration of their lipid-lowering medication
• Subjects who experienced undesirable effects of their lipid-lowering medication and who might, in the opinion of the investigator, require its modification or discontinuation during the 12 weeks of observation period of the study
• Subjects receiving injectable lipid-lowering therapy
• Subjects who are currently using other medication-use-related mobile applications.

Sponsors & Collaborators

• Abbott: lead

Study Sites (1)

Chatlert Mueang Pongchaiyakul

Khon Kaen, 40002, Thailand

Location

Related Publications (1)

• Pongchaiyakul C, Driessen S. Evaluating the effect of mobile applications "My A:Care" and "Smart Coach" on adherence to lipid-lowering treatment in patients with dyslipidemia: a prospective, randomized, open-label clinical study. Front Digit Health. 2025 Jul 7;7:1502990. doi: 10.3389/fdgth.2025.1502990. eCollection 2025.

  PMID: 40692655 DERIVED

MeSH Terms

Conditions

Dyslipidemias

Condition Hierarchy (Ancestors)

Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Jean-Pascal Berrou, MD, Phd

  Abbott

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 1, 2022
• First Posted: May 11, 2022
• Study Start: April 26, 2022
• Primary Completion: August 18, 2022
• Study Completion: November 18, 2022
• Last Updated: February 15, 2023

Record last verified: 2023-02

Locations

TH (1)